The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

Neurology

Volumn 76, Issue 8 SUPPL. 3, 2011, Pages

  Soliven, Betty ^a   Miron, Veronique ^b   Chun, Jerold ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GUANINE NUCLEOTIDE BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ASTROCYTE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL FUNCTION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; REVIEW;

EID: 79952012176     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820d9507     Document Type: Article

References (51)

1. Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005;25:1459-1469. (Pubitemid 40250722)
2. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007;55:1656-1667. (Pubitemid 47612852)
3. Tham CS, Lin FF, Rao TS, Yu N, Webb M. Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 2003;21:431-443. (Pubitemid 37491477)
4. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71. (Pubitemid 351240552)
5. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323:626-635. (Pubitemid 350005137)
6. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101.
7. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007;21:1503-1514. (Pubitemid 46684852)
8. Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 2008;173:1143-1152.
9. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274:13-17.
10. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307.
11. Saini HS, Coelho RP, Goparaju SK, et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J Neurochem 2005;95:1298-1310. (Pubitemid 41779255)
12. Weiner JA, Hecht JH, Chun J. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 1998;398:587-598. (Pubitemid 28364536)
13. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65:2702-2720.
14. Williams A, Piaton G, Lubetzki C. Astrocytes: friends or foes in multiple sclerosis? Glia 2007;55:1300-1312.
15. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005;50:427-434. (Pubitemid 40780846)
16. Pebay A, Toutant M, Premont J, et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 2001;13:2067-2076. (Pubitemid 32664301)
17. Osinde M, Mullershausen F, Dev KK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 2007;52:1210-1218. (Pubitemid 46546406)
18. Rao TS, Lariosa-Willingham KD, Lin FF, et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 2003;990:182-194. (Pubitemid 37244074)
19. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64:1199-1209.
20. Gardell S, Choi JW, Anliker B, Lu M, Kennedy G, Chun J. Evidence for neural S1P receptor signaling in EAE and FTY720 efficacy. Mult Scler 2007;13:S70.
21. Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL. Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 2008;17:2257-2264.
22. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009;5:428-434.
23. Rouach N, Pebay A, Meme W, et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 2006;23:1453-1464.
24. Yamagata K, Tagami M, Torii Y, et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003;41:199-206. (Pubitemid 36262197)
25. Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010;58:1465-1476.
26. Nayak D, Huo Y, Kwang WX, et al. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 2010;166:132-144.
27. Durafourt BA, Lambert C, Johnson TA, Blain M, Bar-Or A, Antel JP. Differential responses of human microglia and blood-derived myeloid cells to FTY720. J Neuroimmunol 2010 Sep 6 [Epub ahead of print].
28. Kimura A, Ohmori T, Ohkawa R, et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007;25:115-124. (Pubitemid 46052981)
29. Herr DR, Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007;8:155-167. (Pubitemid 46043906)
30. Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166:381-392. (Pubitemid 39031241)
31. Kajimoto T, Okada T, Yu H, Goparaju SK, Jahangeer S, Nakamura S. Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol Cell Biol 2007;27:3429-3440. (Pubitemid 46685218)
32. Norman E, Cutler RG, Flannery R, Wang Y, Mattson MP. Plasma membrane sphingomyelin hydrolysis increases hippocampal neuron excitability by sphingosine-1-phosphate mediated mechanisms. J Neurochem 2010;114:430-439.
33. Sim-Selley LJ, Goforth PB, Mba MU, et al. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J Neurochem 2009;110:1191-1202.
34. MacLennan AJ, Carney PR, Zhu WJ, et al. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 2001;14:203-209.
35. Ishii I, Ye X, Friedman B, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P/LP(B2)/EDG-5 and S1P/LP(B3)/EDG-3. J Biol Chem 2002;277:25152-25159.
36. Foster CA, Mechtcheriakova D, Storch MK, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009;19:254-266.
37. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-2694.
38. Kim HJ, Miron VE, Dukala D, et al. Neurobiological effects of sphingosine 1-phosphate receptor in the cuprizone model. FASEB J 2011 (In Press).
39. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457. (Pubitemid 34952287)
40. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349. (Pubitemid 34303689)
41. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153:108-121. (Pubitemid 38950933)
42. Nuesslein-Hildesheim B, Gergely P, Wallstrom E, et al. The S1P1/S1P5 receptor modulator BAF312 reverses neurological deficits in ongoing EAE, reduces specific lymphocyte subsets in healthy volunteers and is a potential new multiple sclerosis therapy. Mult Scler 2009;15:S126.
43. Shimozato T, Tomisato W, Doi H, et al. Preclinical evaluation of a selective sphingosine 1-phosphate receptor-1 modulator: in vitro binding selectivity and effects on experimental autoimmune encephalomyelitis in rats. Mult Scler 2009;15:S78.
44. Choi JW, Herr D, Lee C-W, Teo S, Kennedy G, Chun J. S1P1 receptor signaling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and efficacy of fingolimod (FTY720). Mult Scler 2008;14:S37.
45. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008;131:3092-3102.
46. Qin J, Berdyshev E, Goya J, Natarajan V, Dawson G. Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis. J Biol Chem 2010;285:14134-14143.
47. Kulakowska A, Zendzian-Piotrowska M, Baranowski M, et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett 2010;477:149-152.
48. Hida H, Nagano S, Takeda M, Soliven B. Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes. J Neurosci 1999;19:7458-7467. (Pubitemid 29404602)
49. Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007;74:307-316. (Pubitemid 47368881)
50. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
51. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.